Business
Viking Therapeutics to Participate at Upcoming Investor Conferences
SAN DIEGO, Nov. 4, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the
About this update from Viking Therapeutics, Inc.
[{"type":"text","content":"\n SAN DIEGO, Nov. 4, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. (\"Viking\") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at two upcoming investor conferences. \n \n \n \n \n \n \n \n Details of the company's participation are as follows:\n \n \n Stifel 2025 Healthcare Conference Details: Viking management will participate in a fireside chat and in investor meetings Conference Dates: November 11-13, 2025 Fireside Chat Time/Date: 4:40 – 5:10 p.m. Eastern Time on Tuesday, November 11, 2025 Location: New York, NY\n \n Jefferies 2025 Global Healthcare Conference – London Details: Viking management will deliver a corporate presentation and participate in investor meetings Conference Dates: November 17-20, 2025 Presentation Time/Date: 8:00 – 8:25 a.m. Greenwich Mean Time (3:00 – 3:25 a.m. Eastern Time) on Wednesday, November 19, 2025, webcast available Location: London, UK\n \n A live webcast of the Jefferies presentation may be accessed via a link on the Viking Therapeutics website in the Investors & Media section under Webcasts. Additionally, a replay of the webcast will be available on the Viking website following the conferences. \n \n About Viking Therapeutics, Inc. \n \n Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. The company is evaluating its subcutaneous formulation of VK2735 in a Phase 3 obesity program that includes two Phase 3 clinical trials (VANQUISH-1 and VANQUISH-2). Data from a Phase 1 and a Phase 2 trial evaluating subcutaneous VK2735 demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in a Phase 2 trial in obe...